GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics

Overview

Journal Nucleic Acid Ther

Specialties Biochemistry
Molecular Biology
Pharmacology

Date 2018 May 25

PMID 29792572

Citations 235

Authors

Aaron D Springer

Steven F Dowdy

Affiliations

Soon will be listed here.

Abstract

Short-interfering RNA (siRNA)-induced RNAi responses have great potential to treat a wide variety of human diseases from cancer to pandemic viral outbreaks to Parkinson's Disease. However, before siRNAs can become drugs, they must overcome a billion years of evolutionary defenses designed to keep invading RNAs on the outside cells from getting to the inside of cells. Not surprisingly, significant effort has been placed in developing a wide array of delivery technologies. Foremost of these has been the development of N-acetylgalactosamine (GalNAc) siRNA conjugates for delivery to liver. Tris-GalNAc binds to the Asialoglycoprotein receptor that is highly expressed on hepatocytes resulting in rapid endocytosis. While the exact mechanism of escape across the endosomal lipid bilayer membrane remains unknown, sufficient amounts of siRNAs enter the cytoplasm to induce robust, target selective RNAi responses in vivo. Multiple GalNAc-siRNA conjugate clinical trials, including two phase III trials, are currently underway by three biotech companies to treat a wide variety of diseases. GalNAc-siRNA conjugates are a simple solution to the siRNA delivery problem for liver hepatocytes and have shown the RNAi (and antisense oligonucleotide) field the path forward for targeting other tissue types.

Citing Articles

RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management.

Mohammadi A, Karimian A, Shokri K, Mohammadi A, Hazhir-Karzar N, Bahar R J Cardiovasc Transl Res. 2025; .

PMID: 40080261 DOI: 10.1007/s12265-025-10603-4.

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy.

Ang S, Chia J, Mukherjee D Heart Fail Rev. 2025; .

PMID: 40056371 DOI: 10.1007/s10741-025-10502-5.

Advances and prospects of RNA delivery nanoplatforms for cancer therapy.

Attia M, Kijanka G, Nguyen N, Zhang J, An H Acta Pharm Sin B. 2025; 15(1):52-96.

PMID: 40041887 PMC: 11873661. DOI: 10.1016/j.apsb.2024.09.009.

Lipid-siRNA Conjugates Targeting High PD-L1 Expression as Potential Novel Immune Checkpoint Inhibitors.

Tansou R, Kubo T, Nishida H, Nishimura Y, Mihara K, Yanagihara K Biomolecules. 2025; 15(2).

PMID: 40001596 PMC: 11852376. DOI: 10.3390/biom15020293.

Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease.

de Korte D, Hoekstra M Biomolecules. 2025; 15(2).

PMID: 40001488 PMC: 11852820. DOI: 10.3390/biom15020185.

References

PRICER Jr W, ASHWELL G . Subcellular distribution of a mammalian hepatic binding protein specific for asialoglycoproteins. J Biol Chem. 1976; 251(23):7539-44. View

Khvorova A, Watts J . The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017; 35(3):238-248. PMC: 5517098. DOI: 10.1038/nbt.3765. View

Fiume L, Busi C, Mattioli A . Targeting of antiviral drugs by coupling with protein carriers. FEBS Lett. 1983; 153(1):6-10. DOI: 10.1016/0014-5793(83)80108-2. View

Matsuda S, Keiser K, Nair J, Charisse K, Manoharan R, Kretschmer P . siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem Biol. 2015; 10(5):1181-7. DOI: 10.1021/cb501028c. View

Geuze H, Slot J, Strous G, Lodish H, Schwartz A . Intracellular site of asialoglycoprotein receptor-ligand uncoupling: double-label immunoelectron microscopy during receptor-mediated endocytosis. Cell. 1983; 32(1):277-87. DOI: 10.1016/0092-8674(83)90518-4. View

Chan A, Liebow A, Yasuda M, Gan L, Racie T, Maier M . Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification. Mol Ther Nucleic Acids. 2015; 4:e263. PMC: 4877445. DOI: 10.1038/mtna.2015.36. View

Liebow A, Li X, Racie T, Hettinger J, Bettencourt B, Najafian N . An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol. 2016; 28(2):494-503. PMC: 5280024. DOI: 10.1681/ASN.2016030338. View

Hawkins P, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr O . Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015; 47(8):625-38. PMC: 4720049. DOI: 10.3109/07853890.2015.1068949. View

Meier M, Bider M, Malashkevich V, Spiess M, Burkhard P . Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Biol. 2000; 300(4):857-65. DOI: 10.1006/jmbi.2000.3853. View

10.

Orrantia E, Chang P . Intracellular distribution of DNA internalized through calcium phosphate precipitation. Exp Cell Res. 1990; 190(2):170-4. DOI: 10.1016/0014-4827(90)90181-9. View

11.

Baenziger J, Fiete D . Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes. Cell. 1980; 22(2 Pt 2):611-20. DOI: 10.1016/0092-8674(80)90371-2. View

12.

Sarkar M, Liao J, KABAT E, Tanabe T, ASHWELL G . The binding site of rabbit hepatic lectin. J Biol Chem. 1979; 254(9):3170-4. View

13.

Seymour L, Ferry D, Anderson D, Hesslewood S, Julyan P, Poyner R . Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002; 20(6):1668-76. DOI: 10.1200/JCO.2002.20.6.1668. View

14.

Bridges K, Harford J, ASHWELL G, Klausner R . Fate of receptor and ligand during endocytosis of asialoglycoproteins by isolated hepatocytes. Proc Natl Acad Sci U S A. 1982; 79(2):350-4. PMC: 345729. DOI: 10.1073/pnas.79.2.350. View

15.

Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T . An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015; 21(5):492-7. DOI: 10.1038/nm.3847. View

16.

Schirle N, MacRae I . The crystal structure of human Argonaute2. Science. 2012; 336(6084):1037-40. PMC: 3521581. DOI: 10.1126/science.1221551. View

17.

Prakash T, Kinberger G, Murray H, Chappell A, Riney S, Graham M . Synergistic effect of phosphorothioate, 5'-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA. Bioorg Med Chem Lett. 2016; 26(12):2817-2820. DOI: 10.1016/j.bmcl.2016.04.063. View

18.

Yu R, Graham M, Post N, Riney S, Zanardi T, Hall S . Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice. Mol Ther Nucleic Acids. 2016; 5:e317. PMC: 5014512. DOI: 10.1038/mtna.2016.26. View

19.

Prakash T, Graham M, Yu J, Carty R, Low A, Chappell A . Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014; 42(13):8796-807. PMC: 4117763. DOI: 10.1093/nar/gku531. View

20.

Stockert R, Haimes H, Morell A, Novikoff P, NOVIKOFF A, Quintana N . Endocytosis of asialoglycoprotein-enzyme conjugates by hepatocytes. Lab Invest. 1980; 43(6):556-63. View